# Combination Daclizumab/Denileukin Diftitox to Treat Uveitis

> **NCT00326508** · PHASE2 · COMPLETED · sponsor: **National Eye Institute (NEI)** · enrollment: 5 (—)

## Conditions studied

- Non-infectious Intermediate and Posterior Uveitis

## Interventions

- **DRUG:** Daclizumab

## Key facts

- **NCT ID:** NCT00326508
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05-11
- **Primary completion:** —
- **Final completion:** 2006-12-20
- **Target enrollment:** 5 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326508, "Combination Daclizumab/Denileukin Diftitox to Treat Uveitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00326508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*